The efficacy of T-DM1 in metastatic HER-2+ BC was first demonstrated in the EMILIA trial, where improved OS and PFS were observed in patients treated with T-DM1 in comparison to those treated with Capecitabine plus Lapatinib [35]. This evidence concerns the gene ERBB2 and breast cancer.